NCT02617277 2026-03-04
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
Clinical Trials
10 trialsNCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT02272790 2023-10-03
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
Phase 2 Completed
NCT00648648 2023-09-21
MK-1775-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01357161 2023-09-21
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02482311 2023-07-03
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02610075 2023-07-03
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
AstraZeneca
Phase 1 Completed
NCT04462952 2022-07-25
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02511795 2019-11-07
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02341456 2019-03-25
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Phase 1 Completed